Startseite Medizin Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients

  • Wolfgang Herrmann und Rima Obeid
Veröffentlicht/Copyright: 21. September 2011
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 43 Heft 10

Abstract

The role of hyperhomocysteinemia (HHcy) as a risk marker for cardiovascular diseases in renal patients is a matter of controversy. The remethylation of homocysteine (Hcy) to methionine in the kidneys is of great importance for Hcy clearance. Hcy remethylation is markedly decreased in patients on hemodialysis, but transsulfuration remains mostly unaffected. Markedly increased concentrations of methylmalonic acid (MMA), as a metabolic marker of vitamin B12 deficiency, have been found in approximately 70% of renal patients. This is in contrast to normal concentrations of vitamin B12 usually reported in such patients. We demonstrated in cell culture experiments that the uptake of vitamin B12 by mononuclear cells from renal patients was lower than that taken up by cells from controls. The lowering of MMA and Hcy concentrations in renal patients after B12 administration may indicate the presence of intracellular pre-treatment deficiency. We administered folic acid (5mg) plus vitamin B6 (50mg) and B12 (0.7mg) three times per week intravenously to hyperhomocysteinemic dialysis patients. Hcy decreased after 4weeks by 51%. Hcy was normalized in almost all patients, while serum concentrations of MMA and cystathionine were reduced by 28% and 26%, respectively. Cystathionine, an indicator for the transsulfuration pathway, showed a drastic increase in renal disease and was only slightly lowered by B-vitamin treatment. The increased cystathionine/cysteine ratio in renal patients indicates possible impairment of the catabolism of cystathionine by cystathionase. Moreover, renal failure is associated with severe abnormalities in plasma concentrations of S-adenosyl Hcy (SAH) and S-adenosyl methionine (SAM), as well as the SAM/SAH ratio. This ratio is an indicator of the availability of methyl groups from SAM. Therapeutic doses of B-vitamins in dialysis patients led to a limited improvement in the biomarkers of methylation and probably did not have a significant effect on transmethylation potential in the cells. Furthermore, elevated serum levels of asymmetric dimethylarginine (ADMA) in renal patients, which are associated with a poor outcome for such patients, could be lowered, but this effect was confined to patients who had no anemia. Future studies may consider extending the duration of vitamin treatment, as well as agents that may enhance the hydrolysis of SAH and cystathionine.

Keywords: homocysteine; methylmalonic acid; renal patients; vitamin B12
Corresponding author: Prof. Dr. Wolfgang Herrmann, Department of Clinical Chemistry and Laboratory Medicine, School of Medicine, Saarland University, Kirrberger Str., Gebäude 57 Annexbau, 66421 Homburg, Germany Phone: +49-6841-1630700, Fax: +49-6841-1630703,

References

1. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39:1764–79.10.1093/clinchem/39.9.1764Suche in Google Scholar

2. Finkelstein JD, Martin JJ. Homocysteine. Int J Biochem Cell Biol 2000; 32:385–9.10.1016/S1357-2725(99)00138-7Suche in Google Scholar

3. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 1998; 157(Suppl 2):S40–S44.10.1007/PL00014300Suche in Google Scholar

4. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19:217–46.10.1146/annurev.nutr.19.1.217Suche in Google Scholar

5. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, et al. S-Adenosylmethionine and methylation. FASEB J 1996; 10:471–80.10.1096/fasebj.10.4.8647346Suche in Google Scholar

6. Perna AF, Ingrosso D, Satta E, Romano M, Cimmino A, Galletti P, et al. Metabolic consequences of hyperhomocysteinemia in uremia. Am J Kidney Dis 2001; 38:S85–S90.10.1053/ajkd.2001.27411Suche in Google Scholar

7. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1:228–37.10.1016/0955-2863(90)90070-2Suche in Google Scholar

8. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57:47–53.10.1093/ajcn/57.1.47Suche in Google Scholar PubMed

9. Kim SS, Hirose S, Tamura H, Nagasawa R, Tokushima H, Mitarai T, et al. Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients. Adv Perit Dial 1994; 10:282–5.Suche in Google Scholar

10. Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 1993; 41:S72–7.Suche in Google Scholar

11. Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996; 61:509–12.10.1097/00007890-199602150-00034Suche in Google Scholar PubMed

12. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Drueke TB, Legendre C, et al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994; 9:1103–8.10.1093/ndt/9.8.1103Suche in Google Scholar PubMed

13. Yeun JY. The role of homocysteine in end stage renal disease. Semin Dialysis 1998; 11:95–101.10.1111/j.1525-139X.1998.tb00309.xSuche in Google Scholar

14. Bostom AG, Shemin D, Gohh RY, Beaulieu AJ, Jacques PF, Dworkin L, et al. Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation 2000; 69:2128–31.10.1097/00007890-200005270-00029Suche in Google Scholar

15. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002; 325:1202.10.1136/bmj.325.7374.1202Suche in Google Scholar

16. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356:147–52.10.1016/S0140-6736(00)02456-9Suche in Google Scholar

17. Herrmann W, Schorr H, Geisel J, Riegel W. Homocysteine, cystathionine, methylmalonic acid and B-vitamins in patients with renal disease. Clin Chem Lab Med 2001; 39:739–46.10.1515/CCLM.2001.123Suche in Google Scholar

18. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease [published erratum appears in Circulation 1998;97:711]. Circulation 1998; 97:138–41.10.1161/01.CIR.97.2.138Suche in Google Scholar

19. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94:2743–8.10.1161/01.CIR.94.11.2743Suche in Google Scholar

20. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61:609–14.10.1046/j.1523-1755.2002.00144.xSuche in Google Scholar

21. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57:1727–35.10.1046/j.1523-1755.2000.00018.xSuche in Google Scholar

22. Suliman ME, Stenvinkel P, Qureshi AR, Barany P, Heimburger O, Anderstam B, et al. Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. Am J Kidney Dis 2004; 44:455–65.10.1016/S0272-6386(04)00815-7Suche in Google Scholar

23. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42:864–81.10.1016/j.ajkd.2003.07.016Suche in Google Scholar

24. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004; 15:442–53.10.1097/01.ASN.0000107564.60018.51Suche in Google Scholar

25. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12:2181–9.10.1681/ASN.V12102181Suche in Google Scholar

26. Tsai MY, Aras O, Sozen H, Hanson NQ, Woll PS, Arends VL, et al. Plasma homocysteine levels in living kidney donors before and after uninephrectomy. J Lab Clin Med 2004; 143:340–3.10.1016/j.lab.2004.03.001Suche in Google Scholar

27. Herrmann W, Schorr H, Obeid R, Makowski J, Fowler B, Kuhlmann MK. Disturbed homocysteine and methionine cycle intermediates S-adenosylhomocysteine and S-adenosylmethionine are related to degree of renal insufficiency in type 2 diabetes. Clin Chem 2005; 51:891–7.10.1373/clinchem.2004.044453Suche in Google Scholar

28. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus 2. Kidney Int 1999; 55:1028–35.10.1046/j.1523-1755.1999.0550031028.xSuche in Google Scholar

29. Stabler SP, Marcell PD, Podell ER, Allen RH. Quantitation of total homocysteine, total cysteine, and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry. Anal Biochem 1987; 162:185–96.10.1016/0003-2697(87)90026-1Suche in Google Scholar

30. Janssen MJ, van den Berg M, Stehouwer CD, Boers GH. Hyperhomocysteinaemia: a role in the accelerated atherogenesis of chronic renal failure? Neth J Med 1995; 46:244–51.10.1016/0300-2977(94)00100-6Suche in Google Scholar

31. van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Perit Dial Int 1998; 18:282–9.Suche in Google Scholar

32. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 52:495–502.10.1038/ki.1997.359Suche in Google Scholar PubMed

33. Garibotto G, Saffioti S, Russo R, Verzola D, Cappelli V, Aloisi F, et al. Malnutrition in peritoneal dialysis patients: causes and diagnosis. Contrib Nephrol 2003; 140:112–21.10.1159/000071431Suche in Google Scholar PubMed

34. Kumagai H, Katoh S, Hirosawa K, Kimura M, Hishida A, Ikegaya N. Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney Int 2002; 62:1219–28.10.1111/j.1523-1755.2002.kid558.xSuche in Google Scholar

35. Chen YF, Li PL, Zou AP. Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation 2002; 106:1275–81.10.1161/01.CIR.0000027586.64231.1BSuche in Google Scholar

36. Vermeulen EG, Rauwerda JA, van den BM, de Jong SC, Schalkwijk C, Twisk JW, et al. Homocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial. Eur J Clin Invest 2003; 33:209–15.10.1046/j.1365-2362.2003.01135.xSuche in Google Scholar

37. Arnadottir M, Hultberg B, Nilsson EP, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 1996; 56:41–6.10.3109/00365519609088586Suche in Google Scholar

38. Guttormsen AB, Schneede J, Ueland PM, Refsum H. Kinetics of total plasma homocysteine in subjects with hyperhomocysteinemia due to folate or cobalamin deficiency. Am J Clin Nutr 1996; 63:194–202.10.1093/ajcn/63.2.194Suche in Google Scholar

39. van Guldener C, Kulik W, Berger R, Dijkstra DA, Jakobs C, Reijngoud DJ, et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 1999; 56:1064–71.10.1046/j.1523-1755.1999.00624.xSuche in Google Scholar

40. Stam F, van GC, ter Wee PM, Kulik W, Smith DE, Jakobs C, et al. Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine. Am J Physiol Renal Physiol 2004; 287:F215–23.10.1152/ajprenal.00376.2003Suche in Google Scholar

41. Obeid R, Kuhlmann MK, Kohler H, Herrmann W. Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients. Clin Chem 2005; 51:196–201.10.1373/clinchem.2004.041210Suche in Google Scholar

42. Henning BF, Zidek W, Riezler R, Graefe U, Tepel M. Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12 and folate 1. Res Exp Med (Berl) 2001; 200:155–68.Suche in Google Scholar

43. Moelby L, Rasmussen K, Ring T, Nielsen G. Relationship between methylmalonic acid and cobalamin in uremia. Kidney Int 2000; 57:265–73.10.1046/j.1523-1755.2000.00831.xSuche in Google Scholar

44. Dierkes J, Domrose U, Ambrosch A, Schneede J, Guttormsen AB, Neumann KH, et al. Supplementation with vitamin B12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease. Metabolism 1999; 48:631–5.10.1016/S0026-0495(99)90062-8Suche in Google Scholar

45. Herrmann W, Obeid R, Schorr H, Geisel J. The usefulness of holotranscobalamin in predicting vitamin B12 status in different clinical settings. Curr Drug Metab 2005; 6:47–53.10.2174/1389200052997384Suche in Google Scholar

46. Finkelstein JD, Martin JJ. Methionine metabolism in mammals. Distribution of homocysteine between competing pathways. J Biol Chem 1984; 259:9508–13.10.1016/S0021-9258(17)42728-1Suche in Google Scholar

47. Seetharam B, Li N. Transcobalamin II and its cell surface receptor. Vitam Horm 2000; 59:337–66.10.1016/S0083-6729(00)59012-8Suche in Google Scholar

48. Moestrup SK, Birn H, Fischer PB, Petersen CM, Verroust PJ, Sim RB, et al. Megalin-mediated endocytosis of transcobalamin-vitamin-B12 complexes suggests a role of the receptor in vitamin-B12 homeostasis 1. Proc Natl Acad Sci USA 1996; 93:8612–7.10.1073/pnas.93.16.8612Suche in Google Scholar PubMed PubMed Central

49. Carmel R. Measuring and interpreting holo-transcobalamin (holo-transcobalamin II). Clin Chem 2002; 48:407–9.10.1093/clinchem/48.3.407Suche in Google Scholar

50. Obeid R, Kuhlmann M, Kirsch CM, Herrmann W. Cellular uptake of vitamin B12 in patients with chronic renal failure. Nephron Clin Pract 2005; 99:c42–8.10.1159/000083132Suche in Google Scholar PubMed

51. Righetti M, Ferrario GM, Milani S, Serbelloni P, La RL, Uccellini M, et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 2003; 9:I19–24.Suche in Google Scholar

52. Sunder-Plassmann G, Fodinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000; 11:1106–16.10.1681/ASN.V1161106Suche in Google Scholar PubMed

53. Baragetti I, Furiani S, Dorighet V, Corghi E, Bamonti CF, Buccianti G. Effect of vitamin B12 on homocysteine plasma concentration in hemodialysis patients. Clin Nephrol 2004; 61:161–2.10.5414/CNP61161Suche in Google Scholar PubMed

54. Arnadottir M, Hultberg B. The effect of vitamin B12 on total plasma homocysteine concentration in folate-replete hemodialysis patients. Clin Nephrol 2003; 59:186–9.10.5414/CNP59186Suche in Google Scholar

55. Rajan S, Wallace JI, Brodkin KI, Beresford SA, Allen RH, Stabler SP. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults 1. J Am Geriatr Soc 2002; 50:1789–95.10.1046/j.1532-5415.2002.50506.xSuche in Google Scholar PubMed

56. Herbert V. Staging vitamin B-12 (cobalamin) status in vegetarians. Am J Clin Nutr 1994; 59:1213S–22S.10.1093/ajcn/59.5.1213SSuche in Google Scholar

57. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004; 109:369–74.10.1161/01.CIR.0000109492.65802.ADSuche in Google Scholar

58. Kloor D, Osswald H. S-Adenosylhomocysteine hydrolase as a target for intracellular adenosine action. Trends Pharmacol Sci 2004; 25:294–7.10.1016/j.tips.2004.04.004Suche in Google Scholar

59. Schatz RA, Wilens TE, Sellinger OZ. Decreased transmethylation of biogenic amines after in vivo elevation of brain S-adenosyl-L-homocysteine. J Neurochem 1981; 36:1739–48.10.1111/j.1471-4159.1981.tb00426.xSuche in Google Scholar

60. Kerins DM, Koury MJ, Capdevila A, Rana S, Wagner C. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr 2001; 74:723–9.10.1093/ajcn/74.6.723Suche in Google Scholar

61. Stabler SP, Allen RH. Quantification of serum and urinary S-adenosylmethionine and S-adenosylhomocysteine by stable-isotope-dilution liquid chromatography-mass spectrometry. Clin Chem 2004; 50:365–72.10.1373/clinchem.2003.026252Suche in Google Scholar

62. Finkelstein JD, Kyle WE, Harris BJ. Methionine metabolism in mammals: regulatory effects of S-adenosylhomocysteine. Arch Biochem Biophys 1974; 165:774–9.10.1016/0003-9861(74)90306-3Suche in Google Scholar

63. Kloor D, Ludtke A, Stoeva S, Osswald H. Adenosine binding sites at S-adenosylhomocysteine hydrolase are controlled by the NAD+/NADH ratio of the enzyme. Biochem Pharmacol 2003; 66:2117–23.10.1016/S0006-2952(03)00581-1Suche in Google Scholar

64. Perna AF, Ingrosso D, De Santo NG, Galletti P, Brunone M, Zappia V. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 1997; 8:1899–905.10.1681/ASN.V8121899Suche in Google Scholar

65. Riksen NP, Rongen GA, Blom HJ, Russel FG, Boers GH, Smits P. Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovasc Res 2003; 59:271–6.10.1016/S0008-6363(03)00462-0Suche in Google Scholar

66. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572–5.10.1016/0140-6736(92)90865-ZSuche in Google Scholar

67. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99:1141–6.10.1161/01.CIR.99.9.1141Suche in Google Scholar

68. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358:2127–8.10.1016/S0140-6736(01)07184-7Suche in Google Scholar

69. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358:2127–8.10.1016/S0140-6736(01)07184-7Suche in Google Scholar

70. Kang ES, Cates TB, Harper DN, Chiang TM, Myers LK, Acchiardo SR, et al. An enzyme hydrolyzing methylated inhibitors of nitric oxide synthase is present in circulating human red blood cells. Free Radic Res 2001; 35:693–707.10.1080/10715760100301211Suche in Google Scholar PubMed

71. Nijveldt RJ, Siroen MP, Teerlink T, van Leeuwen PA. Elimination of asymmetric dimethylarginine by the kidney and the liver: a link to the development of multiple organ failure? J Nutr 2004; 134:2848S–52S.10.1093/jn/134.10.2848SSuche in Google Scholar PubMed

72. Nijveldt RJ, Teerlink T, van GC, Prins HA, van Lambalgen AA, Stehouwer CD, et al. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol Dial Transplant 2003; 18:2542–50.10.1093/ndt/gfg452Suche in Google Scholar PubMed

73. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104:2569–75.10.1161/hc4601.098514Suche in Google Scholar PubMed

74. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20:2032–7.10.1161/01.ATV.20.9.2032Suche in Google Scholar PubMed

Published Online: 2011-9-21
Published in Print: 2005-10-1

©2005 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. Homocysteine research – where do we stand and where are we going?
  2. Hyperhomocysteinemia and arteriosclerosis: historical perspectives
  3. Homocysteine and heart failure: a review of investigations from the Framingham Heart Study
  4. Homocysteine and vascular disease in diabetes: a double hit?
  5. Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia
  6. Effects of homocysteine on vascular and tissue adenosine: a stake in homocysteine pathogenicity?
  7. Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease
  8. Carotid narrowing degree and plasma thiol levels in carotid endarterectomy patients
  9. Impairment of homocysteine metabolism in patients with retinal vascular occlusion and non-arteritic ischemic optic neuropathy
  10. Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation
  11. Hyperhomocysteinemia and macromolecule modifications in uremic patients
  12. Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients
  13. Vitamin B12 deficiency is the dominant nutritional cause of hyperhomocysteinemia in a folic acid-fortified population
  14. Homocysteine, folic acid and vitamin B12 in relation to pre- and postnatal health aspects
  15. Evaluation of the technical performance of novel holotranscobalamin (holoTC) assays in a multicenter European demonstration project
  16. A laboratory algorithm with homocysteine as the primary parameter reduces the cost of investigation of folate and cobalamin deficiency
  17. Betaine: a key modulator of one-carbon metabolism and homocysteine status
  18. Molecular targeting by homocysteine: a mechanism for vascular pathogenesis
  19. Anti-inflammatory compound resveratrol suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells in vitro
  20. Homocysteine in relation to cognitive performance in pathological and non-pathological conditions
  21. Homocysteine and B vitamins in mild cognitive impairment and dementia
  22. Homocysteine, type 2 diabetes mellitus, and cognitive performance: The Maine-Syracuse Study
  23. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions
  24. Homocysteine – a newly recognised risk factor for osteoporosis
  25. Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women
  26. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality
  27. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance
  28. Concentrations of homocysteine, related metabolites and asymmetric dimethylarginine in preeclamptic women with poor nutritional status
  29. Asymmetric dimethylarginine, homocysteine and renal function – is there a relation?
  30. Interactions between folate and aging for carcinogenesis
  31. The potential cocarcinogenic effect of vitamin B12 deficiency
  32. The vegetarian lifestyle and DNA methylation
https://doi.org/10.1515/CCLM.2005.182
Schlagwörter für diesen Artikel
homocysteine; methylmalonic acid; renal patients; vitamin B12

Artikel in diesem Heft

  1. Homocysteine research – where do we stand and where are we going?
  2. Hyperhomocysteinemia and arteriosclerosis: historical perspectives
  3. Homocysteine and heart failure: a review of investigations from the Framingham Heart Study
  4. Homocysteine and vascular disease in diabetes: a double hit?
  5. Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia
  6. Effects of homocysteine on vascular and tissue adenosine: a stake in homocysteine pathogenicity?
  7. Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease
  8. Carotid narrowing degree and plasma thiol levels in carotid endarterectomy patients
  9. Impairment of homocysteine metabolism in patients with retinal vascular occlusion and non-arteritic ischemic optic neuropathy
  10. Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation
  11. Hyperhomocysteinemia and macromolecule modifications in uremic patients
  12. Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients
  13. Vitamin B12 deficiency is the dominant nutritional cause of hyperhomocysteinemia in a folic acid-fortified population
  14. Homocysteine, folic acid and vitamin B12 in relation to pre- and postnatal health aspects
  15. Evaluation of the technical performance of novel holotranscobalamin (holoTC) assays in a multicenter European demonstration project
  16. A laboratory algorithm with homocysteine as the primary parameter reduces the cost of investigation of folate and cobalamin deficiency
  17. Betaine: a key modulator of one-carbon metabolism and homocysteine status
  18. Molecular targeting by homocysteine: a mechanism for vascular pathogenesis
  19. Anti-inflammatory compound resveratrol suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells in vitro
  20. Homocysteine in relation to cognitive performance in pathological and non-pathological conditions
  21. Homocysteine and B vitamins in mild cognitive impairment and dementia
  22. Homocysteine, type 2 diabetes mellitus, and cognitive performance: The Maine-Syracuse Study
  23. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions
  24. Homocysteine – a newly recognised risk factor for osteoporosis
  25. Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women
  26. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality
  27. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance
  28. Concentrations of homocysteine, related metabolites and asymmetric dimethylarginine in preeclamptic women with poor nutritional status
  29. Asymmetric dimethylarginine, homocysteine and renal function – is there a relation?
  30. Interactions between folate and aging for carcinogenesis
  31. The potential cocarcinogenic effect of vitamin B12 deficiency
  32. The vegetarian lifestyle and DNA methylation
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 30.12.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2005.182/html?lang=de
Button zum nach oben scrollen